After years of investment to upgrade its manufacturing capabilities, Pacira BioSciences figures it’s time to retire a facility that has been running for more than a decade. | After years spent ...

Pacira BioSciences (NASDAQ:PCRX) stock falls as the company announces plans to cut its workforce by nearly 8% due to ...

Pacira BioSciences plans to lay off 8% of its work force as it decommissioned one of its large-scale manufacturing suites.

Pacira BioSciences, Inc. (NASDAQ: PCRX) disclosed Wednesday that it has implemented a workforce reduction at its Science Center Campus in San Diego, California.The decision follows the company’s move ...

Pacira BioSciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ... I've met with colleagues here in New Jersey and at our Science Center Campus in San Diego.

Pacira (PCRX) BioSciences announced the receipt of U.S. Patent No. 12,156,940 from the U.S. Patent and Trademark Office, the U.S. PTO. The ‘940 patent, entitled "Manufacturing of Bupivacaine ...

PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of ...

SAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences ...

Pacira BioSciences, Inc. (NASDAQ: PCRX) disclosed Wednesday that it has implemented a workforce reduction at its Science Center Campus in San Diego, California.The decision follows the company’s ...

This patent is the first patent from a new family of patents related to EXPAREL produced by the company’s enhanced large-scale manufacturing process in San Diego, which received approval from ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2023 Earnings Conference Call August 2, ... Our San Diego facility is now outperforming volume targets and achieve second quarter margins of 76% for EXPAREL.